Acromegaly
Acromegaly is a rare hormonal disorder that occurs when the pituitary gland produces too much growth hormone, leading to abnormal growth of bones and tissues, particularly in the hands, feet, and face.
Acromegaly: ALXN2420 Treatment Study
We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 80 years old?
- Do you have a diagnosis of acromegaly (a condition caused by a growth hormone-secreting tumor)?
- Have you had any surgery for a pituitary adenoma in the last 6 months?
- Do you have uncontrolled Type 2 diabetes (with an HbA1c higher than 10%)?
- Do you have any significant heart problems, like a recent heart attack or unstable angina in the last 3 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Alxn2420
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Rigshospitalet
Center for Cancer and Organ Diseases
Copenhagen, Denmark
Odense University Hospital
Department of Endocrinology
Odense, Denmark
Central Hospital Of Northern Pest Military Hospital
2nd Internal Medicine
Budapest, Hungary
Sponsor: Alexion Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.